- Published on
Medicine – Acute Myeloid Leukaemia (AML)
Acute myeloid leukaemia (AML) is an aggressive haematological malignancy characterised by the clonal proliferation of immature myeloid precursor cells (myeloblasts) in the bone marrow, peripheral blood and occasionally other tissues.
The accumulation of abnormal myeloblasts suppresses normal haematopoiesis, resulting in bone marrow failure, while infiltration of extramedullary tissues may produce additional clinical manifestations.
AML predominantly affects adults, particularly older adults, and generally requires urgent specialist assessment and treatment.
AML commonly presents with anaemia, infections and bleeding due to bone marrow failure. The presence of Auer rods in circulating blasts strongly supports myeloid differentiation, although Auer rods are not present in every case.
1. Epidemiology
- AML is the most common acute leukaemia in adults.
- The median age at diagnosis is approximately 68–70 years in many populations.
- Incidence increases with age.
- AML may arise de novo or develop following myelodysplastic syndromes, other myeloid neoplasms or previous cytotoxic treatment.
2. Pathophysiology
AML results from acquired genetic and epigenetic abnormalities in haematopoietic precursor cells.
These abnormalities impair normal myeloid differentiation and promote abnormal proliferation and survival.
Pathophysiology Flowchart
3. Clinical Features
AML commonly presents with manifestations of bone marrow failure or leukaemic infiltration.
A. Bone Marrow Failure
| Abnormality | Clinical Manifestations |
|---|---|
| Anaemia | Fatigue, pallor, weakness, dyspnoea |
| Neutropenia | Fever, recurrent or severe infections |
| Thrombocytopenia | Easy bruising, petechiae, epistaxis, gum bleeding |
| Severe marrow dysfunction | Pancytopenia and life-threatening complications |
B. Fever and Infection
Fever may arise from infection associated with neutropenia or from the leukaemic disease itself.
Common presentations include:
- Bacterial infections.
- Pneumonia.
- Oral infections.
- Sepsis.
C. Bleeding and Disseminated Intravascular Coagulation (DIC)
Bleeding may occur due to thrombocytopenia and, in some patients, coagulation abnormalities.
Acute promyelocytic leukaemia (APL) is particularly associated with severe coagulopathy, including DIC and hyperfibrinolysis.
Manifestations may include:
- Petechiae and purpura.
- Epistaxis and gum bleeding.
- Gastrointestinal bleeding.
- Intracranial haemorrhage in severe cases.
D. Hepatosplenomegaly
Hepatomegaly and splenomegaly may occur due to leukaemic infiltration.
Lymphadenopathy is less prominent than in acute lymphoblastic leukaemia but can occur.
E. Gingival Infiltration
Leukaemic infiltration of the gums can produce gingival enlargement or hypertrophy.
This is particularly associated with AML showing monocytic differentiation.
F. Orbital and Other Extramedullary Infiltration
AML may produce extramedullary tumours known as myeloid sarcomas.
Possible sites include:
- Orbit.
- Skin (leukaemia cutis).
- Gingiva.
- Lymph nodes.
- Bone and soft tissues.
- Central nervous system, less commonly.
Orbital infiltration may present with proptosis or visual disturbance.
G. Hyperleukocytosis and Leukostasis
Markedly elevated circulating blast counts may impair microvascular circulation.
Possible manifestations include:
- Dyspnoea and hypoxaemia.
- Headache.
- Confusion.
- Visual disturbances.
- Neurological deficits.
Leukostasis is a life-threatening complication requiring urgent specialist management.
4. Peripheral Blood Film
The peripheral blood film may demonstrate circulating myeloblasts, sometimes containing Auer rods.
Auer Rods
Auer rods are needle-shaped, reddish-purple cytoplasmic inclusions formed from fused primary azurophilic granules.
They support myeloid differentiation and are an important diagnostic clue.
Auer Rod Schematic
Simplified educational illustration; not an actual blood film.
5. Diagnosis and Investigations
A. Full Blood Count
Possible findings include:
- Anaemia.
- Thrombocytopenia.
- Elevated, normal or reduced white cell count.
- Circulating blasts.
B. Bone Marrow Examination
Bone marrow aspiration and trephine biopsy assess blast burden, morphology and marrow architecture.
Traditionally, AML was diagnosed when myeloblasts represented at least 20% of nucleated cells in blood or marrow.
However, current classifications recognise certain genetically defined AML entities that can be diagnosed below the traditional 20% threshold. Specific requirements vary between classification systems.
C. Flow Cytometry and Immunophenotyping
Common myeloid markers include:
- CD13.
- CD33.
- CD117.
- Myeloperoxidase (MPO).
- CD34, expressed in many but not all AML cases.
The exact immunophenotype varies by AML subtype.
D. Cytogenetic and Molecular Testing
Genetic analysis is essential for classification, prognosis and treatment selection.
| Genetic Abnormality | Clinical Significance |
|---|---|
| PML::RARA, t(15;17) | Acute promyelocytic leukaemia |
| RUNX1::RUNX1T1, t(8;21) | Core-binding factor AML |
| CBFB::MYH11, inv(16) | Core-binding factor AML |
| NPM1 mutation | Defines an important molecular AML subgroup |
| FLT3 mutation | Influences risk assessment and targeted treatment |
| CEBPA mutation | Certain bZIP mutations define a favourable-risk subgroup |
| TP53 mutation | Often associated with adverse-risk disease |
E. Other Investigations
- Coagulation profile, including PT, aPTT, fibrinogen and D-dimer.
- Renal function and electrolytes.
- Liver function.
- LDH and uric acid.
- Blood cultures when infection is suspected.
- Baseline cardiac assessment before anthracycline-based chemotherapy when indicated.
Diagnostic Flowchart
6. Important AML Subtype: Acute Promyelocytic Leukaemia (APL)
Acute promyelocytic leukaemia (APL) is a distinct subtype of AML characterised by the PML::RARA fusion, usually caused by t(15;17).
APL is particularly important because of its association with severe, potentially fatal bleeding.
When APL is suspected, all-trans retinoic acid (ATRA) should be started immediately under specialist direction, without waiting for genetic confirmation, alongside urgent management of coagulopathy.
Characteristic Features of APL
- PML::RARA fusion gene.
- Abnormal promyelocytes.
- Possible bundles of Auer rods (“faggot cells”).
- Severe bleeding tendency.
- DIC and hyperfibrinolysis.
Treatment of APL
APL is commonly treated with:
- ATRA: All-trans retinoic acid.
- Arsenic trioxide (ATO).
- Additional treatment according to risk and clinical circumstances.
- Urgent blood product support and correction of coagulopathy.
7. Treatment of AML
Treatment depends on age, fitness, AML subtype, genetic risk and patient preferences.
A. Intensive Chemotherapy
Fit patients with appropriate AML subtypes may receive induction chemotherapy to achieve remission.
A traditional regimen is 7+3 chemotherapy:
- Cytarabine: Administered for seven days.
- Anthracycline: Such as daunorubicin or idarubicin, administered for three days.
Targeted agents may be added when indicated by molecular findings.
B. Consolidation Therapy
After remission, further treatment aims to eliminate residual leukaemic cells and reduce relapse risk.
Options include:
- High-dose cytarabine-based chemotherapy.
- Allogeneic haematopoietic stem cell transplantation in selected patients.
C. Lower-Intensity Treatment
For patients unsuitable for intensive chemotherapy, options may include:
- Azacitidine plus venetoclax.
- Decitabine-based regimens.
- Other lower-intensity or targeted treatments according to AML subtype and clinical circumstances.
D. Targeted Therapy
Examples include:
- FLT3 inhibitors for eligible FLT3-mutated AML.
- IDH inhibitors in selected IDH-mutated AML.
- Other molecularly targeted treatments according to disease characteristics and availability.
E. Stem Cell Transplantation
Allogeneic haematopoietic stem cell transplantation can provide potentially curative treatment for selected patients, particularly those with higher-risk disease or relapse.
Transplant decisions depend on relapse risk, treatment response, comorbidities and donor availability.
F. Supportive Care
- Red cell and platelet transfusions when indicated.
- Prompt treatment of infections.
- Prevention and management of tumour lysis syndrome.
- Management of DIC and bleeding.
- Antimicrobial prophylaxis in selected patients.
- Fertility preservation counselling when appropriate.
Treatment Flowchart
Simplified general AML pathway. APL follows a distinct urgent treatment pathway.
8. Prognosis
AML prognosis varies considerably according to:
- Age and performance status.
- Cytogenetic and molecular abnormalities.
- AML subtype.
- Response to treatment.
- Measurable residual disease (MRD).
- Eligibility for transplantation.
Older teaching materials sometimes quote an overall cure rate of approximately 30%, but this is not a reliable universal figure for contemporary AML.
Some younger patients with favourable-risk AML have substantially better outcomes, whereas older or adverse-risk patients may have poorer outcomes.
9. AML vs ALL
| Feature | AML | ALL |
|---|---|---|
| Cell lineage | Myeloid precursors | Lymphoid precursors |
| Typical population | Predominantly adults | Common in children; also occurs in adults |
| Auer rods | May be present | Absent |
| MPO | Often positive | Usually negative |
| Gingival infiltration | Particularly associated with monocytic AML | Less characteristic |
| CNS involvement | Less common at presentation | More clinically prominent in some subtypes |
| Main treatment | Chemotherapy, targeted agents ± transplant | Multi-agent chemotherapy, immunotherapy ± transplant |
10. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Disease | Aggressive myeloid malignancy |
| Typical population | Adults, especially older adults |
| Main mechanism | Myeloblast proliferation and marrow failure |
| Clinical features | Fever, anaemia, infection, bleeding |
| Blood film | Myeloblasts ± Auer rods |
| Diagnostic investigations | Bone marrow, flow cytometry, cytogenetics and molecular testing |
| Traditional blast threshold | ≥20%, with genetic exceptions |
| Gingival infiltration | Associated with monocytic AML |
| Orbital infiltration | May represent myeloid sarcoma |
| DIC association | Particularly acute promyelocytic leukaemia |
| APL genetic hallmark | PML::RARA, usually t(15;17) |
| APL emergency treatment | Immediate ATRA when suspected |
| Intensive treatment | Cytarabine plus anthracycline-based induction |
| Lower-intensity option | Azacitidine plus venetoclax |
| Potentially curative procedure | Allogeneic stem cell transplantation |
| Prognosis | Highly variable according to risk and response |
11. Key Examination Pearls
- AML is the most common acute leukaemia in adults.
- Bone marrow failure produces anaemia, infection and bleeding.
- Auer rods support a diagnosis of myeloid leukaemia but are not always present.
- Gingival hypertrophy is classically associated with AML with monocytic differentiation.
- Orbital infiltration may occur as myeloid sarcoma.
- APL is associated with PML::RARA and severe coagulopathy.
- Suspected APL requires immediate ATRA and urgent specialist management.
- Bone marrow examination, immunophenotyping and molecular testing are essential.
- Intensive induction chemotherapy commonly uses cytarabine and an anthracycline.
- Allogeneic stem cell transplantation is considered for selected patients.
- Prognosis depends strongly on genetic risk and treatment response.
An adult presenting with fever, pallor, recurrent infections, bruising or bleeding, together with circulating myeloblasts and Auer rods, should raise suspicion of acute myeloid leukaemia.
AML with DIC, particularly suspected acute promyelocytic leukaemia, requires immediate specialist treatment because life-threatening haemorrhage may occur before definitive diagnostic confirmation.
Kembara Xtra – Medicine Revision Notes